Q-Med´s new CFO appointed

Q-Med´s new CFO appointed

Alexander Kotsinas will be Q-Med's new CFO. He takes up his appointment February
1, 2008.

-	“It is not without pride that we can announce that Alexander Kotsinas will be
joining Q-Med's senior management team in the role of company CFO. Alexander has
experience or working in fast-growing, entrepreneurial organizations and has
succeeded very well, with the support of good judgement and a solid education.
We have high expectations of working with him as soon as he has completed his
present assignment,” says Bengt Ågerup, President and CEO.

Alexander Kotsinas' most recent position was that of CFO at Life Europe AB after
a longer period of time as CFO for the mobile operator Tre (Hi3G Access AB). He
has also worked at Ericsson and Investor. Alexander is a Business Administration
graduate from Handelshögskolan i Stockholm (The Stockholm School of Economics)
and a Master of Civil Engineering from Kungliga Tekniska Högskolan (The Royal
Institute of Technology).






Queries should be addressed to: 
Bengt Ågerup, CEO
Tel: +46 (0)70 974 9025
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70 974 9015

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets and sells primarily medical
implants. The majority of the products are based on the company's patented
technology, NASHA™ for the production of stabilized non-animal hyaluronic acid. 
The product portfolio today contains: RESTYLANE for the filling out of lips and
facial wrinkles and for facial contouring, MACROLANE for body contouring,
DUROLANE  for the treatment of osteoarthritis of the hip and knee joints, DEFLUX
for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary
bladder) in children, ZUIDEX, for the treatment of stress urinary incontinence
in women and SOLESTA, for the treatment of fecal incontinence. Sales are made
through the company's own subsidiaries or distributors in over 70 countries.
Q-Med today has just over 600 co-workers, with approximately 400 at the
company's head office and production facility in Uppsala, Sweden. Q-Med AB is
listed in the Large Cap segment of the OMX Nordic Exchange in Stockholm.

NASHA, MACROLANE, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product
names within the RESTYLANE family are trademarks that belong to Q-Med AB.